Davunetide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •2 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
The phase 2/3 trial in progressive supranuclear palsy failed to show efficacy, and the original developer became insolvent.
Not approved for any therapeutic use. Currently in phase 3 only for the rare ADNP syndrome indication.
⚠️Important Warnings
- •NOT APPROVED FOR GENERAL USE: Davunetide failed the PSP trial and is only being investigated for rare ADNP syndrome.
- •FAILED EFFICACY: The phase 2/3 PSP trial did not demonstrate therapeutic benefit over placebo.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Unscheduled | Not FDA-approved. Investigational for ADNP syndrome. Available as research chemical. |
| United Kingdom | Unscheduled | Not approved by MHRA. Research purposes only. |
| Canada | Unscheduled | Not approved by Health Canada. Research chemical. |
| European Union | Unscheduled | Not approved by EMA. Investigational status varies. |
| Australia | Unscheduled | Not approved by TGA. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 10+ community reports
View community protocolsCritical Safety Information#
Davunetide is not approved for any therapeutic use. While it demonstrated a favorable safety profile in the PSP trial, it failed to show efficacy. It is currently being investigated only for the rare genetic condition ADNP syndrome.
Legal and Regulatory Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Not approved | Investigational for ADNP syndrome |
| United Kingdom | Not approved | Research chemical |
| Canada | Not approved | Research chemical |
| European Union | Not approved | Investigational |
| Australia | Not approved | Not scheduled |
Risk Assessment Context#
Davunetide belongs to the Neuroprotective category of research peptides. Risk assessment for Davunetide should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.
Risk Categories#
The following risk categories have been identified for Davunetide based on available evidence and regulatory assessments:
Failed PSP Clinical Trial#
The phase 2/3 trial in progressive supranuclear palsy failed to show efficacy, and the original developer became insolvent.
Limited Approved Indications#
Not approved for any therapeutic use. Currently in phase 3 only for the rare ADNP syndrome indication.
Regulatory Status by Jurisdiction#
The regulatory and legal status of Davunetide varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.
| Country | Status | Notes |
|---|---|---|
| United States | unscheduled | Not FDA-approved. Investigational for ADNP syndrome. Available as research chemical. |
| United Kingdom | unscheduled | Not approved by MHRA. Research purposes only. |
| Canada | unscheduled | Not approved by Health Canada. Research chemical. |
| European Union | unscheduled | Not approved by EMA. Investigational status varies. |
| Australia | unscheduled | Not approved by TGA. |
Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.
Important Warnings#
The following warnings apply to Davunetide:
- NOT APPROVED FOR GENERAL USE: Davunetide failed the PSP trial and is only being investigated for rare ADNP syndrome.
- FAILED EFFICACY: The phase 2/3 PSP trial did not demonstrate therapeutic benefit over placebo.
These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.
Related Reading#
Frequently Asked Questions About Davunetide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.